Literature DB >> 15485861

Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase.

Feng Jiang1, Junying Bao, Pengfei Li, Santo V Nicosia, Wenlong Bai.   

Abstract

The maintenance of telomere length is required for continued cell proliferation, and approximately 85-90% of human cancers, including ovarian epithelial cancers (OCa), show high activity of telomerase. In the present study we report that 1,25-dihydroxyvitamin D(3) (1,25(OH)(2) VD)(3)induces OCa cell apoptosis by down-regulating telomerase. Quantitative reverse transcription-PCR analysis shows that 1,25(OH)(2)VD(3) decreases the level of human telomerase reverse transcriptase (hTERT) mRNA, the catalytic subunit of telomerase. The decrease is not due to transcriptional repression through the putative vitamin D response element present in the 5' regulatory region of hTERT gene. Instead, 1,25(OH)(2) VD(3) decreases the stability of the hTERT mRNA. Stable expression of hTERT in OCa cells decreases their response to 1,25(OH)(2)VD(3)-induced growth suppression. Although the cell cycle progression of these clones stably expressing hTERT is inhibited by 1,25(OH)(2)VD(3) to a similar degree as that of the parental cells, these clones are more resistant to apoptosis induced by 1,25(OH)(2)VD(3) .In contrast to parental cells, which lose proliferation potential after the 1,25(OH)(2)VD(3) treatment, hTERT-expressing clones resume rapid growth after withdrawal of 1,25(OH)(2)VD(3). Overall, the study suggests that the down-regulation of telomerase activity by 1,25(OH)(2)VD(3) and the resulting cell death are important components of the response of OCa cells to 1,25(OH)(2)VD(3)-induced growth suppression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15485861     DOI: 10.1074/jbc.M410395200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Association Between Prediagnostic Serum 25-Hydroxyvitamin D Concentration and Glioma.

Authors:  Victoria Zigmont; Amy Garrett; Jin Peng; Michal Seweryn; Grzegorz A Rempala; Randall Harris; Christopher Holloman; Thomas E Gundersen; Anders Ahlbom; Maria Feychting; Tom Borge Johannesen; Tom Kristian Grimsrud; Judith Schwartzbaum
Journal:  Nutr Cancer       Date:  2015-08-28       Impact factor: 2.900

2.  Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: pooled analysis in five studies within the Ovarian Cancer Association Consortium.

Authors:  Galina Lurie; Lynne R Wilkens; Pamela J Thompson; Michael E Carney; Rachel T Palmieri; Paul D P Pharoah; Honglin Song; Estrid Hogdall; Susanne Kruger Kjaer; Richard A DiCioccio; Valerie McGuire; Alice S Whittemore; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; Susan J Ramus; Marc T Goodman
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

3.  RIPK1 binds to vitamin D receptor and decreases vitamin D-induced growth suppression.

Authors:  Waise Quarni; Panida Lungchukiet; Anfernee Tse; Pei Wang; Yuefeng Sun; Ravi Kasiappan; Jheng-Yu Wu; Xiaohong Zhang; Wenlong Bai
Journal:  J Steroid Biochem Mol Biol       Date:  2017-02-01       Impact factor: 4.292

4.  Vitamin D suppresses leptin stimulation of cancer growth through microRNA.

Authors:  Ravi Kasiappan; Yuefeng Sun; Panida Lungchukiet; Waise Quarni; Xiaohong Zhang; Wenlong Bai
Journal:  Cancer Res       Date:  2014-09-24       Impact factor: 12.701

5.  Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system.

Authors:  Yingyu Ma; Wei-Dong Yu; Alejandro A Hidalgo; Wei Luo; Remi Delansorne; Candace S Johnson; Donald L Trump
Journal:  Cell Cycle       Date:  2013-02-06       Impact factor: 4.534

Review 6.  Current understanding of risk factors for ovarian cancer.

Authors:  Thanasak Sueblinvong; Michael E Carney
Journal:  Curr Treat Options Oncol       Date:  2009-07-15

7.  Circulating 25-hydroxyvitamin D and risk of epithelial ovarian cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers.

Authors:  Wei Zheng; Kim N Danforth; Shelley S Tworoger; Marc T Goodman; Alan A Arslan; Alpa V Patel; Marjorie L McCullough; Stephanie J Weinstein; Laurence N Kolonel; Mark P Purdue; Xiao-Ou Shu; Kirk Snyder; Emily Steplowski; Kala Visvanathan; Kai Yu; Anne Zeleniuch-Jacquotte; Yu-Tang Gao; Susan E Hankinson; Chinonye Harvey; Richard B Hayes; Brian E Henderson; Ronald L Horst; Kathy J Helzlsouer
Journal:  Am J Epidemiol       Date:  2010-06-18       Impact factor: 4.897

8.  1, 25-dihydroxyvitamin D3 decreases adriamycin-induced podocyte apoptosis and loss.

Authors:  Min-shu Zou; Jian Yu; Guo-ming Nie; Wei-sun He; Li-man Luo; Hong-tao Xu
Journal:  Int J Med Sci       Date:  2010-08-24       Impact factor: 3.738

Review 9.  Potent 19-norvitamin D analogs for prostate and liver cancer therapy.

Authors:  Atsushi Kittaka; Akihiro Yoshida; Kun-Chun Chiang; Masashi Takano; Daisuke Sawada; Toshiyuki Sakaki; Tai C Chen
Journal:  Future Med Chem       Date:  2012-10       Impact factor: 3.808

10.  Circulating vitamin d and risk of epithelial ovarian cancer.

Authors:  Alan A Arslan; Tess V Clendenen; Karen L Koenig; Johan Hultdin; Kerstin Enquist; Asa Agren; Annekatrin Lukanova; Hubert Sjodin; Anne Zeleniuch-Jacquotte; Roy E Shore; Göran Hallmans; Paolo Toniolo; Eva Lundin
Journal:  J Oncol       Date:  2009-08-27       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.